Industry Strength Score
10/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NEUROPACE INC (NPCE) Stock Price & Overview
NASDAQ:NPCE • US6412881053
Current stock price
16.9 USD
+0.36 (+2.18%)
Last:
The current stock price of NPCE is 16.9 USD. Today NPCE is up by 2.18%. In the past month the price increased by 25.78%. In the past year, price increased by 38.06%.
NPCE Key Statistics
52-Week Range7.5625 - 18.975
Current NPCE stock price positioned within its 52-week range.
1-Month Range13.27 - 17.79
Current NPCE stock price positioned within its 1-month range.
- Market Cap
- 569.023M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.66
- Dividend Yield
- N/A
NPCE Stock Performance
Today
+2.18%
1 Week
-2.59%
1 Month
+25.78%
3 Months
+9.32%
Longer-term
6 Months +66.40%
1 Year +38.06%
2 Years +27.33%
3 Years +230.80%
5 Years -31.54%
10 Years N/A
NPCE Stock Chart
NPCE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NPCE. When comparing the yearly performance of all stocks, NPCE is one of the better performing stocks in the market, outperforming 81.33% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NPCE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NPCE. NPCE may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NPCE Earnings
On March 3, 2026 NPCE reported an EPS of -0.08 and a revenue of 26.59M. The company beat EPS expectations (48.21% surprise) and beat revenue expectations (5.14% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 3, 2026
PeriodQ4 / 2025
EPS Reported-$0.08
Revenue Reported26.588M
EPS Surprise 48.21%
Revenue Surprise 5.14%
NPCE Forecast & Estimates
14 analysts have analysed NPCE and the average price target is 20.25 USD. This implies a price increase of 19.85% is expected in the next year compared to the current price of 16.9.
For the next year, analysts expect an EPS growth of 1.09% and a revenue growth 0.25% for NPCE
Analysts
Analysts84.29
Price Target20.25 (19.82%)
EPS Next Y1.09%
Revenue Next Year0.25%
NPCE Index Membership
NPCE is currently included in the following stock indexes tracked on ChartMill.
NPCE Financial Highlights
Over the last trailing twelve months NPCE reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 30.53% compared to the year before.
Income Statements
Revenue(TTM)99.99M
Net Income(TTM)-21.46M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.33% | ||
| ROE | -112.79% | ||
| Debt/Equity | 3.09 |
Chartmill High Growth Momentum
EPS Q2Q%55.56%
Sales Q2Q%23.86%
EPS 1Y (TTM)30.53%
Revenue 1Y (TTM)25.13%
NPCE Ownership
Ownership
Inst Owners74.69%
Shares33.67M
Float25.96M
Ins Owners2.38%
Short Float %3.53%
Short Ratio4.61
NPCE Industry Overview
NPCE operates in the Health Care Equipment sub-industry within the Health Care sector. This group contains 127 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
61/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
13%
Outperformed 13% of sub-industries
3 Month Rank
10%
Outperformed 10% of sub-industries
6 Month Rank
10%
Outperformed 10% of sub-industries
Industry Fundamentals & Breadth
- Members
- 127
- New Highs
- 2.4%
- New Lows
- 13.4%
- Average ROE
- 17.1%
- Average Profit Margin
- 20.3%
- Average Operating Margin
- 22.5%
- Average P/E
- 28.2
- Average Fwd P/E
- 26.5
- Average Debt/Equity
- 0.5
NPCE Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 38.95 | 161.187B | ||
| ABT | ABBOTT LABORATORIES | 14.41 | 158.701B | ||
| SYK | STRYKER CORP | 20.95 | 120.688B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.49 | 84.935B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.37 | 46.827B | ||
| IDXX | IDEXX LABORATORIES INC | 37.78 | 43.972B | ||
| BDX | BECTON DICKINSON AND CO | 10.85 | 41.376B | ||
| RMD | RESMED INC | 17.35 | 30.874B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 10.59 | 27.142B | ||
| DXCM | DEXCOM INC | 23.1 | 22.153B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.01 | 15.499B | ||
| PEN | PENUMBRA INC | 63.85 | 12.772B | ||
| GMED | GLOBUS MEDICAL INC - A | 19.67 | 11.874B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NPCE
Company Profile
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 209 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Company Info
IPO: 2021-04-22
NEUROPACE INC
455 N. Bernardo Avenue
Mountain View CALIFORNIA US
CEO: Michael Favet
Employees: 209
Phone: 16502372700
NEUROPACE INC / NPCE FAQ
Can you describe the business of NEUROPACE INC?
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 209 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
What is the current price of NPCE stock?
The current stock price of NPCE is 16.9 USD. The price increased by 2.18% in the last trading session.
Does NPCE stock pay dividends?
NPCE does not pay a dividend.
How is the ChartMill rating for NEUROPACE INC?
NPCE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about NEUROPACE INC (NPCE) stock?
14 analysts have analysed NPCE and the average price target is 20.25 USD. This implies a price increase of 19.85% is expected in the next year compared to the current price of 16.9.
Can you provide the growth outlook for NEUROPACE INC?
The Revenue of NEUROPACE INC (NPCE) is expected to grow by 0.25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for NEUROPACE INC?
NEUROPACE INC (NPCE) has a market capitalization of 569.02M USD. This makes NPCE a Small Cap stock.